Metabolic Syndrome, Inflammation, and Risk of Cognitive Decline

This study has been completed.

Sponsor:

Collaborators:

Paul Beeson Faculty Scholars Program

University of California, San Francisco

Information provided by:

National Institute on Aging (NIA)

ClinicalTrials.gov Identifier:

NCT00099567

First received: December 16, 2004

Last updated: October 31, 2005

Last verified: December 2004

History of Changes

Purpose

The purpose of this study is to determine if the metabolic syndrome is a risk factor for cognitive decline and if this association is modified by inflammation.

Condition
Cognitive Decline


Study Type:	Observational
Study Design:	Allocation: Random Sample Observational Model: Natural History Time Perspective: Longitudinal Time Perspective: Prospective
Official Title:	Metabolic Syndrome, Inflammation, and Risk of Cognitive Decline

Resource links provided by NLM:

MedlinePlus related topics: Metabolic Syndrome

Genetic and Rare Diseases Information Center resources: Familial Alzheimer Disease Abdominal Obesity Metabolic Syndrome

U.S. FDA Resources

Further study details as provided by National Institute on Aging (NIA):


Estimated Enrollment:	2632
Study Start Date:	January 1997
Estimated Study Completion Date:	December 2002

Detailed Description:

The metabolic syndrome is a clustering of several commonly occurring disorders that include abdominal obesity, high triglycerides, low HDL cholesterol, high blood pressure, and insulin resistance. This study was conducted to determine if, as hypothesized, the presence of the metabolic syndrome is associated with more cognitive decline and greater risk of developing cognitive impairment, and whether this risk is affected by the level of inflammatory markers in the blood.

This 5-year prospective observational study was conducted from 1997 to 2002 at community clinics in two locations. A total of 2632 black and white participants, aged 70 to 79 years, were recruited from the 3075 participants in the Health, Aging and Body Composition (ABC) study conducted during the same period. Participants were screened for presence of metabolic syndrome, cognitive status, inflammatory markers, and a clinic examination was administered, when the study began and at the year 3 and 5 follow-up visits.

Eligibility


Ages Eligible for Study:	70 Years to 79 Years (Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Aged 70 to 79
White or Black
Community-dwelling in Memphis, TN or Pittsburgh, PA vicinity
Well-functioning (no difficulty in walking a quarter of a mile or going up 10 steps without resting)

Exclusion Criteria:

Any difficulty with activities of daily living
Clinical dementia
Inability to communicate with interviewer
Intention of moving out of vicinity in the next year
Active treatment for cancer in the previous 3 years
Participation in a trial involving a lifestyle intervention

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00099567

Locations


United States, Pennsylvania

Pittsburgh, Pennsylvania, United States
United States, Tennessee

Memphis, Tennessee, United States

Sponsors and Collaborators

National Institute on Aging (NIA)

Paul Beeson Faculty Scholars Program

University of California, San Francisco

Investigators


Principal Investigator:	Kristine Yaffe, MD	University of California, San Francisco

More Information

Publications:

Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, Tylavsky FA, Newman AB. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA. 2004 Nov 10;292(18):2237-42.

Yaffe K, Lindquist K, Penninx BW, Simonsick EM, Pahor M, Kritchevsky S, Launer L, Kuller L, Rubin S, Harris T. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology. 2003 Jul 8;61(1):76-80.

Kalmijn S, Foley D, White L, Burchfiel CM, Curb JD, Petrovitch H, Ross GW, Havlik RJ, Launer LJ. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study. Arterioscler Thromb Vasc Biol. 2000 Oct;20(10):2255-60.


ClinicalTrials.gov Identifier:	NCT00099567 History of Changes
Other Study ID Numbers:	IA0066 1N01AG62106 1R01AG021918
Study First Received:	December 16, 2004
Last Updated:	October 31, 2005
Health Authority:	United States: Federal Government

Keywords provided by National Institute on Aging (NIA):


Metabolic Syndrome Alzheimer's Disease Cognitive Impairment Inflammation

Additional relevant MeSH terms:


Syndrome Inflammation Metabolic Syndrome X Cognition Disorders Disease Pathologic Processes	Insulin Resistance Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases Neurocognitive Disorders Mental Disorders

ClinicalTrials.gov processed this record on September 23, 2016

To Top